SMi presents Europe's leading 10th annual conference and exhibition: Pre-Filled Syringes Europe 2018

SMi Group17 - 18 January 2018, London, UK.
Join the calendar event highlight for the medical device industry at Europe's leading 10th annual conference and exhibition on Pre-Filled Syringes when it returns to Central London on 17th and 18th January 2018. Pre-Filled Syringes Europe will once again provide a perfect platform to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and booming market.

Building on the success of its sell-out global 2017 PFS series of events which saw 100+ attendees join shows in London, Boston and San Diego, the agenda for Pre-Filled Syringes Europe 2018 has been carefully tailored to arm you with the key requirements and tools to adapt to an ever-changing medical landscape in areas that are critical to those working within parenteral drug delivery and injectable devices.

Featured Speakers:

  • Alphons Fakler, Group Head Risk Management, Novartis Pharma
  • Bettine Boltres, Technical Account Manager, West Pharmaceutical Services
  • Elizabeth Baker, Group Manager Licensing Division, MHRA
  • Marcel Mueller, Device Project Leader, Novartis
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Carsten Worsoe, Principal Scientist, CMC Analytical Support, Novo Nordisk
  • Vikas Jaitely, Senior Manager CMC Regulatory Intelligence and Pharmaceutical Science, Merck
  • Susanne Joerg, Head of Formulation Development, Lonza
  • Orla Downes, Head of Business Development Unit, Barts Health Pharmaceuticals
  • Barry Knight, Device Program Lead, UCB Celltech
  • Sudeshna Dutta Ray, Senior Engineer, Advanced Device Technology and Innovation, Amgen
  • Alexander Jung, Senior Manager, Technology and Innovation, Drug Delivery and Devices, Boehringer Ingelheim
  • Christian Dechant, Primary Packaging Director, Boehringer Ingelheim

Sponsors include: Früh Verpackungstechnik Ag, Mitsubishi Gas Chemical, Nemera, Panasonic, West Pharmaceutical Services, Worrell and more

Key Topics for 2018:

  • Engage with the latest regulatory updates and guidelines for ultimate product compliance and efficiency
  • Discuss the emerging hot topic of combination products and benchmark against other industry-leaders
  • Participate in the increased focus towards digital connectivity and smart devices for improved patient adherence
  • Follow approaches to human factors and end-user engagement from formulation to after-market development
  • Witness the latest insights into the broader market trends of increased biologics attention and how to address these challenges head on

This event will sell-out. For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA approves expanded use of Gardasil 9 to include…

The U.S. Food and Drug Administration approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Pfizer announces Executive Leadership Team

Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new...